Literature review of clinical analysis of hereditary neuropathy with liability to pressure palsies.

This review summarizes the clinical and electromyography (EMG) characteristics and peripheral myelin protein 22 (PMP22) gene-related diseases of hereditary neuropathy with liability to pressure palsies (HNPP). Clinical, EMG, and laboratory data of patients diagnosed with HNPP at our institution from 2022 to 2023 were retrospectively reviewed. Relevant literature from January 2003 to June 2024 was retrieved from PubMed using the keywords "hereditary neuropathy with liability to pressure palsies" and "HNPP." Clinical manifestations, EMG characteristics, and gene detection results of HNPP were summarized. All patients exhibited transient neurological symptoms and tested positive for the PMP22 deletion. EMG revealed multiple peripheral nerve abnormalities. Sixty-eight studies meeting the inclusion and exclusion criteria were included, comprising 124 HNPP cases (including six from our study), with 67 males and 57 females. The mean age of onset and diagnosis for the 124 cases were 26.5 ± 18 years and 32.7 ± 18.9 years, respectively, with a maximum onset-to-diagnosis interval of 40 years. Typical weakness and numbness in vulnerable areas were observed in 63.7% of cases, with 62% experiencing recurrent episodes. Atypical symptoms were present in 29.8%, while 6.5% were asymptomatic. Patients exhibited pain and muscular dystrophy (17.7%), pes cavus (12.1%), and a family history of HNPP (64.5%). Among symptomatic patients, triggers were traction or compression (57.8%), temperature changes (3.4%), or unclear (38.8%). Heterozygous PMP22 deletions and other PMP22 gene mutations were found in 77.4% and 22.6% of cases, respectively.